[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.204.52.4. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
JAMA Oncology Clinical Evidence Synopsis
January 2017

Lymphadenectomy for Treatment of Early-Stage Endometrial Cancer

Author Affiliations
  • 1Department of Gynaecological Oncology, Cheltenham General Hospital, Gloucestershire Hospitals NHS Foundation Trust, Cheltenham, England
  • 2Department of Gynaecological Oncology, Musgrove Park Hospital, Taunton, England
 

Copyright 2016 American Medical Association. All Rights Reserved.

JAMA Oncol. 2017;3(1):117-118. doi:10.1001/jamaoncol.2016.4873
Abstract

Clinical Question  What is the association between lymphadenectomy and survival, disease recurrence, and surgical morbidity in women with presumed early-stage, low-grade endometrial carcinoma?

Bottom Line  The evidence from randomized clinical trials suggests that lymphadenectomy does not improve survival or decrease disease recurrence in women with early-stage, low-grade endometrial carcinoma. Furthermore lymphadenectomy is associated with an increase in both short- and long-term surgery-related systemic morbidity.

×